The main manufacturing site is spread across a 22-acre area located near the capital city, Dhaka, which houses facilities for manufacturing tablets, capsules, intravenous fluids, liquids, creams, ointments, suppositories, metered dose inhalers, ophthalmic drops, large volume parenterals, sterile ophthalmics, prefilled syringes, lyophilized injectables etc. The site has its own utility infrastructure to ensure adequate generation and distribution of electricity with an installed capacity of 10 MW, besides having water purifying and liquid nitrogen generation facilities. Our penicillin units (both API and formulation) are located separately at Kaliakoir, 21 km from the main site.
Tablets & Capsules
Our state-of-the-art Oral Solid Dosage facility has been audited and approved by the US FDA. This facility incorporates modern technological advancements with automated material handling systems and multilevel designs to enable gravity feed between processing stages. The building design has also allowed maximum engineering maintenance access without entering into the production areas. This facility, consisting of five lines with an installed annual capacity to produce 5 billion tablets on a single shift, has been audited and approved by the regulatory authorities of Australia, EU, Gulf States, Brazil, and Taiwan, while awaiting inspection and approvals from USFDA. It provides larger capacity and a stronger platform to manufacture value added generics for highly regulated markets, and also offering the company as an attractive contract manufacturing partner.
Beximco Pharma is among the very few companies in the world who successfully converted CFC based formulations to ozone friendly HFA Inhalers well ahead of the deadline in compliance with the Montreal Protocol. BPL is now the single largest producer of metered dose inhalers (MDI) in Bangladesh, and the only company to contract manufacture inhaler products for a global MNC. The MDI manufacturing units, designed and installed with the technical collaboration from Pamasol, have an annual production capacity of 15 million canisters. The capacity of MDI production is being expanded in line with our expectation and growing demand from overseas markets. Beximco is also a leading manufacturer of Dry Powder Inhaler (DPI) in the country with its range of products for treating asthma and respiratory diseases. DPIs are available in innovative patient-friendly packaging with alu-alu blister pack to protect the medicine from moisture. BPL′s unique and simple Bexihaler® device, imported from Europe, consisting of 8 pins, ensures optimum dose delivery. Currently the facility has the capacity to produce 36 million units of DPI every year.
Beximco Pharma′s ophthalmic facility was the first such facility to be accredited by the regulatory authorities of EU and Australia and the Company has differentiated itself by maintaining global quality standards as a result of which it became the first company in the country to export sterile eye drops to Europe.
Intravenous (IV) Fluid
Our ISO 9001: 2015 certified Intravenous (IV) fluid unit, being among the most technologically advanced plants in the region, produces wide range of large volume parenterals (LVPs). This IV unit, designed and installed in collaboration with Pharmaplan of Germany, ensures the highest quality standard during manufacture and extreme care is taken in every stages of operation in order to maintain stringent class conditions. The whole production process provides absolute sterile manufacturing conditions which has been ensured by way of a series of fully automated manufacturing procedures including robotics and latest FFS (Form-Fill-Seal) bottle pack aseptic system. All these are performed under a class 100 clean room in a single working cycle, cautiously avoiding any environmental exposure or human contact during manufacturing.
Syrups and Suspensions
Beximco Pharma has a broad range of liquid formulations like syrups etc. and semisolid dosage forms including creams and ointments. At present the capacity of liquid dosage facility is 37 million units per annum and the Company has taken up expansion program along with further upgradation of the existing unit to meet the growing demand. The Company currently has the capacity to produce 6 million units of creams and ointments and 10 million units of suppositories.
Nasal sprays are a solution or suspension of medicine sprayed into the nostrils, usually to produce a local effect directly inside the nose. Beximco Pharma’s range of products in the form of Nasal Spray includes Beclomethasone, Oxymetazoline, Mometasone, Olopatadine, Fluticasone etc.
Pre-filled syringe (PFS) provide both convenience and accuracy to self-administered drugs. With their ease of use and improved safety features, PFS has become one of the most widely used drug delivery systems today. Beximco Pharma offers high precision PFS line that employs sophisticated technology and the entire filling operation is done under laminar flow in a Class 100 environment to provide absolute sterile conditions. Current portfolio includes a complete series of blood thinning product Enoxaparin.
Lyophilization is a complex and facility intensive operation where Beximco Pharma has demonstrated its skill through quick and successful adoption of this relatively new technology. The Company, within a short span of time, has emerged as a major player in this area with its range of PPIs and other formulations.
Oral Soluble Film (OSF)
Beximco Pharma became the first pharmaceutical company in Bangladesh to introduce Oral Soluble Film (OSF), an innovative oral drug delivery system applied on top of the tongue where it gets dissolved within seconds providing immediate action. Onsat OSF (Ondansetron), an anti-emetic drug, is available as 4 and 8 mg soluble films. OSF offers fast, accurate dosing in a safe, efficacious format that is convenient and portable, without the need for water or measuring devices.